Novavax Starts COVID-19, Flu Combination Vaccine Trial - Novavax (NASDAQ:NVAX)

Novavax Inc (NASDAQ:NVAX) has enrolled the first participants in a Phase 1/2 study to test its combined flu and COVID-19 vaccine.
The trial combines Novavax's recombinant protein-based NVX-CoV2373 and NanoFlu vaccine candidates and patented saponin-based Matrix-M adjuvant in a single formulation (COVID-NanoFlu Combination Vaccine).
Both NVX-CoV2373 and NanoFlu have previously demonstrated strong results as standalone vaccines in Phase 3 trials.
Related: Novavax's COVID-19 Vaccine Candidate Showed Immune Response, Protection Against Variants.
The trial will evaluate the safety, tolerability, and immune response to NanoFlu in 640 healthy adults 50 to 70 years of age.
Results are expected during the first half of 2022.
Read Next: Novavax's COVID-19 Vaccine, Flu Shot Co-administration Preserved Efficacy, Likely 'Viable Strategy'.
Price Action: NVAX stock is down 0.83% at $268.35 during the market session on the last check Wednesday.

To add Benzinga News as your preferred source on Google, click here.